RxDoctor Payments Data

Corbin Hodder, DO

Pulmonary Disease · Stuart, FLNPI 1073723565

Payments from drug & device makers

$7,887in general payments, 2019–2025

Across 46 payments — averaging $171.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • AstraZeneca$839
  • Mallinckrodt Hospital Products Inc.$142
  • Abiomed$125
  • GSK$119
  • Auris Health, Inc.$20

What the payments were for

  • Travel & lodging$1,84023%
  • Food & beverage$2,60033%
  • Education$3,00038%
  • Gifts$4476%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical35$6,642
AstraZeneca7$839
Mallinckrodt Hospital Products Inc.1$142
Abiomed1$125
GSK1$119
Auris Health, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,887 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$144,939
Medicare patients
480
Services billed
1,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter271$224,860
Spiriva RespimatTiotropium Bromide64$48,606
Dupixent PenDupilumab12$43,922
Breo ElliptaFluticasone/Vilanterol53$37,495
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$36,392
Stiolto RespimatTiotropium Br/Olodaterol Hcl34$20,432
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$16,697
Incruse ElliptaUmeclidinium Bromide42$15,821
SymbicortBudesonide/Formoterol Fumarate51$15,062
Bevespi AerosphereGlycopyrrolate/Formoterol Fum26$11,258
Fluticasone-SalmeterolFluticasone Propion/Salmeterol48$9,362
Albuterol Sulfate HfaAlbuterol Sulfate271$8,812
Arnuity ElliptaFluticasone Furoate28$6,147
Ventolin HfaAlbuterol Sulfate59$3,926
BreynaBudesonide/Formoterol Fumarate17$3,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$119$301,021421 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$839$62,713116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →